|
 |
|||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals to Webcast Presentation at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference SAN DIEGO – April 26, 2004 – ADVENTRX Pharmaceuticals (BB:AVRX) will webcast its presentation at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference, on Tuesday, April 27 at 9:00 am EDT. Nicholas Jon Virca, President and CEO, will provide an update on the latest Company developments. Interested parties may access the live webcast and replay it by visiting the ADVENTRX website at www.adventrx.com. It is suggested that participants access the webcast 15 minutes before the start of the live webcast. The webcast replay will be archived on the News and Events page in the Investors section of ADVENTRX's web site until May 28, 2004. About ADVENTRX ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information on ADVENTRX and BlockAide/CR can be found on the Company's website at www.adventrx.com. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contacts: The Ruth Group Investors: Stephanie Carrington 646-536-7017 Media: Cynthia Isaac, Ph.D. 646-536-7028 |
